Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03808961 Not yet recruiting - Parkinson's Disease Clinical Trials

Niacin for Parkinsons Disease

NAPS
Start date: April 1, 2019
Phase: N/A
Study type: Interventional

(1) To examine the blood, urine and spinal fluid of persons with Parkinson's to look for evidence of inflammation and; (2) whether 18 months of vitamin B3(niacin or niacinamide) supplementation may reduce the inflammation and/or improve PD motor and non-motor symptoms.

NCT ID: NCT03808675 Not yet recruiting - Parkinson's Disease Clinical Trials

Aerobic Exercise in Parkinson's Disease

LTAE-PD
Start date: April 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Parkinson's disease (PD) is an incurable brain illness that afflicts more than one million Americans, including many aging Veterans. PD places an unbearable burden on the individual due to progressive impairment of movement and mental function. As a result, patients lose critical abilities such as driving and can become isolated. Although drugs and surgery help movement problems, their benefits are temporary and may cause side effects. Drugs provide limited and temporary benefit for cognition and do not prevent dementia. Animal and preliminary human studies on aerobic exercise show promising results in helping a broad spectrum of symptoms. However, due to limited and inconsistent research results, the long term effects of aerobic exercise on brain health and clinical features in PD is unknown. The investigators will conduct a clinical trial to test the long term effects of aerobic exercise on the brain tissue, movement, mental functions, and driving in PD. If effective, aerobic exercise can be implemented immediately as a low cost, easily accessible treatment in PD.

NCT ID: NCT03806517 Not yet recruiting - Parkinson Disease Clinical Trials

Bone Mineral Density Changes Among Clinical Subtypes of Parkinson's Disease

Start date: January 15, 2019
Phase:
Study type: Observational

The bone loss in Parkinson's disease (PD) emerges as a non-motor symptom with motor and non-motor outcomes, such as fracture and musculoskeletal pain. Bone mineral density (BMD) is decreasing in patients with PD, when compared to sex and age-matched healthy controls. The changes in BMD according to clinical subtypes of PD is unknown. We are planning to compare the BMD status between the tremor dominant and postural instability and gait difficulty type of PD.

NCT ID: NCT03799614 Not yet recruiting - Parkinson Disease Clinical Trials

Vibration Impact on Parkinson's Tremor

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

The primary purpose of this study is to test the safety, tolerability and efficacy of vibration (delivered by an experimental device called RMBand that is worn on the subject's arm) on parkinsonian tremor. The RMBand was developed by Resonate Forward, LLC (RF). This RMBand is designed to administer a vibration to the wearer to decrease or stop tremor in persons with Parkinson's disease (PD).

NCT ID: NCT03797378 Not yet recruiting - Stroke Clinical Trials

Movement-2-Music: Lakeshore Examination of Activity, Disability, and Exercise Response Study

M2M LEADERS
Start date: January 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to test the effects of an innovative exercise program referred to as movement-2-music (M2M) on health and fitness outcomes in adults with physical/mobility disabilities. One hundred and eight participants with physical/mobility disabilities will be recruited and randomly enrolled into one of two groups: a) M2M or b) waitlist control. The primary aim of this study is to determine the effects of a 12-week M2M program on health and fitness in participants with physical/mobility disabilities who are in one of three functional mobility groups: 1) Group I - only able to exercise while sitting, 2) Group II - able to exercise sitting and standing with/without support, and 3) Group III - able to exercise one side of the body more than the other side. The second aim is to compare the observed effects of the program in this study to a previous M2M study that groups participants based on disability type. The third aim of this study is to test whether adherence (defined as attendance to the 12-week program) affects the effects of M2M in participants with physical/mobility disabilities. The potential influences of different functional mobility and disabilities of participants on how the program affects participants' health and fitness outcomes will also be tested.

NCT ID: NCT03794661 Not yet recruiting - Parkinson's Disease Clinical Trials

Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool

EVIDENT
Start date: February 28, 2019
Phase: N/A
Study type: Interventional

The objective of this clinical investigation is to characterize the clinical performance of Abbott's Clinician Programmer Electrode Screening Mode tool (InformityTM tool) in programming InfinityTM deep brain stimulation (DBS) systems for patients with Parkinson's disease (PD) or essential tremor (ET).

NCT ID: NCT03791983 Not yet recruiting - Parkinson Disease Clinical Trials

Precision Medical Diagnosis and Acupuncture Treatment for Parkinson's Disease

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This study integrates traditional Chinese medicine syndromes and pulse diagnosis, and uses laser vibration overlay and functional cerebral angiography to understand the efficacy of scalp acupuncture against Parkinson's Disease.

NCT ID: NCT03790670 Not yet recruiting - Parkinson Disease Clinical Trials

Biomarker Assessments of Leukine During Treatment of Parkinson's Disease

Start date: January 15, 2019
Phase: Phase 1
Study type: Interventional

First, the investigators will determine the safety of a 6 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend). This 6 month (n=5) pilot study will extend the prior 2 month observation tests towards the goal of assessing the safety of Leukine for treatment of Parkinson's disease (PD). Clinical signs and symptoms will be measured by personal well-being, physical, and neurological examinations (UPDRS Parts I, II, III, and IV assessments) and blood tests (CBC with differential, total T cell count, and a comprehensive metabolic sera panel). Second, we will assess regimen tolerability administered in a dose reduction, from 6 µg/kg/day without interruption, to 3 µg/kg/day with 2 day drug holidays. The investigators will examine over a time of 6 months, effects of treatment on defined adaptive immune deficits in PD as measured by analysis of peripheral blood mononuclear cells collected before, during, and after cessation of Leukine administration. Individual T cell parameters will be assessed and will include links between T cell function and subset analyses and clinical neurological signs and symptoms. In addition, the functional stability of the immune deficits will be assess in PD by examining T cell subsets in PD patients in this study against prior results. The investigators will also determine whether the immune deficits of PD are consistent during baseline data collection, and the potential Leukine-induced motor control and mobility improvements will be determined by UPDRS part I, II, III, and IV scores off treatment and on treatment.

NCT ID: NCT03782753 Not yet recruiting - Parkinson Disease Clinical Trials

Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease

Start date: December 17, 2018
Phase:
Study type: Observational

Parkinson's Disease (PD) is a progressive neurodegenerative disease characterized clinically by bradykinesia, resting tremor, rigidity, and postural instability. Little is known about the mechanisms underlying neuronal degeneration in PD and currently, no treatment is available to halt disease progression in PD. The pathophysiological characterisation of phenomena occurring in the time window between the pathological start of the disease and the onset of motor symptoms is crucial to develop potential neuroprotective agents. Several genes have been discovered providing important insights on the pathogenesis of PD. Mutations of Leucine-rich repeat kinase 2 (LRRK2) are associated with 2-5% of all PD cases in North American Caucasians. LRRK2 is an enzyme that in humans is encoded by the autosomal dominant Parkinson's disease-8 (PARK8) gene, which is associated with an increased risk of PD. Clinical and digital biomarkers, blood and cerebrospinal fluid (CSF) biomarkers and molecular positron emission tomography (PET) imaging, with specific radioligands, provide invaluable insights to help understand and characterise disease pathophysiology. The investigators aim to characterize molecular phenomena underlying LRRK2 PD with the hope of providing further insights into possible mechanisms taking place in PD and to help identify targets for disease-modifying therapeutics.

NCT ID: NCT03781167 Not yet recruiting - Clinical trials for Parkinson's Disease (PD)

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Start date: January 16, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of ABBV-951 in subjects with Parkinson's disease (PD).